lower forecast remain
action lower earn estim follow review outlook
domest drug price revis competit environ
opdivo maintain expect medium-term profit growth
continu think compani could continu rais profit
onward reiter outperform rate target price
potenti return introduc forecast
invest overview opdivo appear increasingli rapidli head
toward peak valu domest met success approv
treatment non-small-cel lung cancer also indic
gastric cancer oversea sale via partner
high also royalti incom rise due growth sale
europ royalti rate high well sale merck
keytruda expect opdivo domest sale domest
royalti incom believ next round revis
appli opdivo sale reach think
maxim product valu near term could sustain profit
catalysts/risk checkmat trial confirm overal surviv
os effect opdivo approv lung cancer treatment
could posit share price surpris think opposit
would hold true ono ten product opdivo slate
approv believ year present opportun
investor focu shift product opdivo includ
cachexia chronic cardiac failur
valuat base target price ep
previous forward price-to-earnings
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
issuanc retir stock
net chang cash
number share mn
incom expens
profit tax
cash equival
royalti bm
compani mention price
